WUXI
WXIDrugs in Pipeline
22
Phase 3 Programs
11
Upcoming Catalysts
5
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
5 upcoming, 0 past
5 mg BGM0504 injection
Overweight or Obesity
Guideline-directed medical therapy (GDMT) for heart failure
Pulmonary Hypertension
Mesenchymal Stem Cells
Knee Osteoarthritis
CU-20101 treatment for Moderate to Severe Glabellar Striae
Glabellar Frown Lines
CU-40102 Spray
AGA
A+C Vaccine
Group A, C Polysaccharide Meningitis
A+C+hib Conjugate Vaccine
Meningitis
ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm
Tuberculosis
Paclitaxel and Cisplatin
Stage III Esophageal Squamous Cell Carcinoma
Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks
Pediatric Hereditary Kidney Diseases
Gemcitabine +Carboplatin
Non-small Cell Lung Cancer
Selinexor
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
1.Abiraterone Acetate Tablets
Prostatectomy
Pemetrexed (1)
Leptomeningeal Metastases
MSC-IFNα
Locally Advanced or Metastatic Solid Tumors
RMP-A03 - Dose 1
Pterygium
D3S-001
KRAS P.G12C
CU-20401
Safety
Subcutaneous injection of CU-20401
Efficacy and Safety
D3S-002
Advanced Solid Tumors With MAPK Pathway Mutations
PEG-somatropin
Dwarfism
NWRD08 administered by electroporation
High-grade Squamous Intraepithelial Lesion (HSIL)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
5 mg BGM0504 injection | Phase 3 | Overweight or Obesity | - | - |
Guideline-directed medical therapy (GDMT) for heart failure | Phase 3 | Pulmonary Hypertension | - | - |
Mesenchymal Stem Cells | Phase 3 | Knee Osteoarthritis | - | - |
CU-20101 treatment for Moderate to Severe Glabellar Striae | Phase 3 | Glabellar Frown Lines | - | - |
CU-40102 Spray | Phase 3 | AGA | - | - |
A+C Vaccine | Phase 3 | Group A, C Polysaccharide Meningitis | - | - |
A+C+hib Conjugate Vaccine | Phase 3 | Meningitis | - | - |
ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm | Phase 3 | Tuberculosis | - | - |
Paclitaxel and Cisplatin | Phase 3 | Stage III Esophageal Squamous Cell Carcinoma | - | - |
Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks | Phase 3 | Pediatric Hereditary Kidney Diseases | - | - |
Gemcitabine +Carboplatin | Phase 3 | Non-small Cell Lung Cancer | - | - |
Selinexor | Phase 2 | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | - | - |
1.Abiraterone Acetate Tablets | Phase 2 | Prostatectomy | - | - |
Pemetrexed (1) | Phase 2 | Leptomeningeal Metastases | - | - |
MSC-IFNα | Phase 2 | Locally Advanced or Metastatic Solid Tumors | - | - |
RMP-A03 - Dose 1 | Phase 2 | Pterygium | - | - |
D3S-001 | Phase 2 | KRAS P.G12C | - | - |
CU-20401 | Phase 2 | Safety | - | - |
Subcutaneous injection of CU-20401 | Phase 2 | Efficacy and Safety | - | - |
D3S-002 | Phase 2 | Advanced Solid Tumors With MAPK Pathway Mutations | - | - |
PEG-somatropin | Phase 2 | Dwarfism | - | - |
NWRD08 administered by electroporation | Phase 2 | High-grade Squamous Intraepithelial Lesion (HSIL) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in WUXI's drug pipeline?→
CatalystAlert tracks 22 drug candidates in WUXI's (WXI) pipeline across Phase 3, Phase 2. Its lead program is 5 mg BGM0504 injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is WUXI's next FDA catalyst?→
WUXI's (WXI) next tracked catalyst is a Phase 3 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track WXI biotech catalysts?→
Add WXI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow WUXI's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.